A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Trial Profile

A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Letrozole (Primary) ; Palbociclib (Primary) ; Goserelin
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 18 May 2017 Planned End Date changed from 30 Apr 2021 to 30 Jun 2021.
    • 18 May 2017 Planned primary completion date changed from 31 May 2019 to 31 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top